Treatment of Vancomycin-Resistant Enterococci: Focus on Daptomycin

Area of Science:

• Infectious Diseases
• Pharmacology
• Microbiology

Background:

• Vancomycin-resistant Enterococci (VRE) infections pose a significant clinical challenge due to limited effective treatment options.
• Existing anti-VRE agents may have adverse effects and drug interactions, necessitating alternative therapies.

Purpose of the Study:

• To review the efficacy and safety of daptomycin in treating VRE infections.
• To summarize key findings from clinical studies on daptomycin for VRE.

Main Methods:

• Review of relevant clinical studies on daptomycin for VRE infections.
• Analysis of daptomycin dosing, safety profiles (creatinine phosphokinase elevation), and treatment outcomes.

Main Results:

• Higher daptomycin doses (≥6 mg/kg) demonstrated safety and were associated with successful infection outcomes and microbiological clearance.
• High-dose daptomycin is crucial for VRE infections with elevated minimum inhibitory concentration (MIC) values (3-4 μg/mL).
• Daptomycin is effective and safe for various serious VRE infections, including catheter-associated bloodstream and intra-abdominal infections, and in specific populations like oncology patients.

Conclusions:

• Higher doses of daptomycin are recommended for treating VRE infections, especially those with elevated MICs.
• Daptomycin is a valuable and safe therapeutic option for serious VRE infections across different clinical scenarios.
• Previous daptomycin use and prosthetic devices are associated with VRE infections exhibiting higher daptomycin MIC values.